Renal Unit, Dept. of Internal Medicine, Univ. Affiliated Hospital Hamburg Barmbek, Rübenkamp 220, 22291 Hamburg, Germany.
Am J Physiol Renal Physiol. 2012 Oct;303(7):F1015-25. doi: 10.1152/ajprenal.00380.2011. Epub 2012 Jul 18.
Podocyte foot process retraction is a hallmark of proteinuric glomerulonephritis. Cytoskeletal rearrangement causes a redistribution of slit membrane proteins from the glomerular filtration barrier towards the cell body. However, the underlying signaling mechanisms are presently unknown. Recently, we have developed a new experimental model of immune-mediated podocyte injury in mice, the antipodocyte nephritis (APN). Podocytes were targeted with a polyclonal antipodocyte antibody causing massive proteinuria around day 10. Rho-kinases play a central role in the organization of the actin cytoskeleton of podocytes. We therefore investigated whether inhibition of Rho-kinases would prevent podocyte disruption. C57/BL6 mice received antipodocyte serum with or without daily treatment with the specific Rho-kinase inhibitor HA-1077 (5 mg/kg). Immunoblot analysis demonstrated activation of Rho-kinase in glomeruli of antipodocyte serum-treated mice, which was prevented by HA-1077. Increased Rho-kinase activity was localized to podocytes in APN mice by immunostainings against the phosphorylated forms of Rho-kinase substrates. Rho-kinase inhibition significantly reduced podocyte loss from the glomerular tuft. Periodic acid staining demonstrated less podocyte hypertrophy in Rho-kinase-inhibited APN mice, despite similar amounts of immune complex deposition. Electron microscopy revealed reduced foot process effacement compared with untreated APN mice. Internalization of the podocyte slit membrane proteins nephrin and synaptopodin was prevented by Rho-kinase inhibition. Functionally, Rho-kinase inhibition significantly reduced proteinuria without influencing blood pressure. In rats with passive Heymann nephritis and human kidney biopsies from patients with membranous nephropathy, Rho-kinase was activated in podocytes. Together, these data suggest that increased Rho-kinase activity in the podocyte may be a mechanism for in vivo podocyte foot process retraction.
足细胞足突回缩是蛋白尿性肾小球肾炎的一个标志。细胞骨架重排导致裂孔膜蛋白从肾小球滤过屏障重新分布到细胞体。然而,目前尚不清楚其潜在的信号机制。最近,我们在小鼠中开发了一种新的免疫介导的足细胞损伤实验模型,即抗足细胞肾炎(APN)。多克隆抗足细胞抗体靶向足细胞,导致约第 10 天出现大量蛋白尿。Rho 激酶在足细胞肌动蛋白细胞骨架的组织中起着核心作用。因此,我们研究了抑制 Rho 激酶是否会防止足细胞破坏。C57/BL6 小鼠接受抗足细胞血清,或在接受抗足细胞血清的同时每天接受特异性 Rho 激酶抑制剂 HA-1077(5mg/kg)治疗。免疫印迹分析表明,抗足细胞血清治疗的小鼠肾小球中 Rho 激酶被激活,HA-1077 可阻止其激活。免疫染色显示,在 APN 小鼠中,Rho 激酶活性增加定位于足细胞,该活性是由 Rho 激酶底物的磷酸化形式来定位的。Rho 激酶抑制可显著减少肾小球足突中足细胞的丢失。过碘酸染色显示,尽管免疫复合物沉积量相似,但 Rho 激酶抑制的 APN 小鼠的足细胞肥大程度较低。电子显微镜显示,与未治疗的 APN 小鼠相比,Rho 激酶抑制可减少足突融合。Rho 激酶抑制可防止足细胞裂孔膜蛋白nephrin 和 synaptopodin 的内化。功能上,Rho 激酶抑制可显著减少蛋白尿,而不影响血压。在被动 Heymann 肾炎大鼠和膜性肾病患者的肾活检中,Rho 激酶在足细胞中被激活。综上所述,这些数据表明,足细胞中 Rho 激酶活性的增加可能是体内足细胞足突回缩的一种机制。